In as much as the 2-phosphate ester of clindamycin is being clinically evaluated as an injectable form of clindamycin, it was of interest to compare its in vitro and in vivo characteristics with the 3-phosphate ester.
Analysis of the kinetics of hydrolysis of the esters in three in vitro enzyme systems indicate marked differences, with the 3-ester being hydrolyzed much more slowly and much less extensively than the 2-ester. An in vivo study in rats revealed lower blood levels for the 3-phosphate when compared with the 2-phosphate and may be related to the rates of hydrolysis.
Metabolism studies indicate that the esters are metabolized in a similar manner to the parent clindamycin.
The antibiotic clindamycm* (I) is 7-deoxy-7(S)-chlorolincomycin7), for the structure Fresh human blood, 250ml, was treated with 2,000 units of heparin. After standing 30minutes, the blood was centrifuged for 15minutes at 5,000rpm in a refrigerated centrifuge. Two-mlaliquots of the resulting plasma were spiked with 5mcg/ml of either clindamycin-2-phosphate or clidamycin-3-phosphate from aqueous stock solutions (1 mg/ml) of each. One sample was immediately frozen as the 0-hour control and the remainder were then incubated for 1/2, 1, 2, 4, 8, 16, 24and48hours After agitation and nitration, the filtrate was reduced in volume and subsequently brought to the original 2ml volume with tris buffer. All hydrolysis samples weretreated in a like manner as they were removed from the bath. The resulting solutions were frozen subsequent to quantitation. To generate data for a Lineweaver-Burk plot, the same procedure was followed using alkaline phosphatase ; however, all samples were incubated for 6hours. Rat Liver Homogenate A 20/1 dilution of stock rat liver homogenate in 0.5MpH 8.0 tris buffer was prepared. Two-ml aliquots were spiked with 5 mcg/ml of clindamycin-2-or 3-phosphate. The samples were treated as described above except that a 72-hour sample was included for the 3-phosphate.
Quantitation The disc plate technique was used for quantitating the hydrolysis samples. Clindamycin -HC1 was the primary standard and serial dilutions (in plasma or tris buffer) of 50
.3125mcg/ml were used. Twosets of standard discs (20mcl solution on 6.35mm S & S paper discs) were plated on each tray with a complete set of 2-and 3- and the method of inducing infections have been described in detail previously6). Subcutaneous treatment of the infected mice with the esters was initiated immediately with incremental doses of the antibiotic contained in 0.2ml of water. The mice were treated once daily for four days. Evaluation of antibiotic activity was based, after 7days, on the median protective dose (CD50) of the ester compared to the CD50 calculated for a clindamycin-treated control group. Calculations were made with an IBM360computer using the method of Spearman and Karber13). Antibiotic concentrations, including clindamycin and active metabolic products, found in whole blood were determined in 150g Sprague-Dawley rats*. Clindamycin or its phosphate monoesters were dissolved in 0.05m PO4 buffer, pH 7.0 at 3mg/ml and threerat groups dosed subcutaneously with 0.5ml/rat (10mg/kg). At specified times, free flowing whole blood sufficient to saturate 1/4" S & S paper discs (0.02ml/disc) was collected from the rats by clipping portions of their tails.
The saturated discs were placed on Sarcina lutea seeded medium, pH 8.0 in assay trays and incubated at 32°C for 16~18
hours. A standard assay curve was determined on each tray using serially diluted clindamycin solutions of 5~0.156 mcg/ml. Antibiotic cncentrations in whole blood were estimated from the standard curve.
Evaluation of absorption was based on a comparison of the amounts of antibiotic in the blood as measured by the area under the time vs. concentration curves, time at which 50% of the area (T50) was under the curve and the time of maximumconcentrations.
Results were calculated using an IBM 360computer.
Results and Discussion
In vitro Studies The quantitative results for the various in vitro enzyme systems are given in Tables 1, 2 and 3 . Factors accoung for the theoretical value of clindamycin which could be generated from the amount of clindamycin phosphate used, and the quantitation of clindamycin free base (present in the hydrolysis solutions at pH 8) using clindamycin à"HC1 as a standard, were applied to the calculation of clindamycin phosphate concentrations.
Since the quantitations were carried out using duplicate experiments spotted on two bacteria seeded trays, the four standard regression lines (2 per tray) were analyzed by an ANOCV program with a Hewlett-Packard 9100A comduter for significance of the regression coefficients a and b in the least squares line.
Y=a+hlogx:
Based on these calculations the data were pooled to form a single standard curve for quantitation. Regression statistics (r, Sv.xyv for these lines appear in Tables 1, 2 Fig. 2 . The curves reflect and lack of observable reaction for 3-phosphate in plasma may reflect a low specific activity, for these substrates, of serum phosphatases. It has been demonstrated1^that certain lincomycin-3 esters migrate readily to the 4-position markedly reducing the ease with which they are hydrolyzed. There is some TLC evidence that clindamycin-3-phosphate undergoes a similar reaction and may be removed from the reaction pool. This could also contribute to the low extent of hydrolysis for this particular ester in the three systems studied.
In an attempt to elucidate the nature of the difference in the hydrolysis rates of the two^esters, alkaline phosphatase reactions were run in pH 6 tris buffer. Although the reaction appeared to be somewhat faster at this pH (based only on the size of the inhibition zone), the relative reaction rates of the 2-and 3-phosphates at pH 6 were not significantly different from those at pH 8. At this point it seemed likely that determination of Km values would indicate some basis for the differences in the hydrolyses.
Reaction velocities were determined at various substrate concentrations using 6-hour hydrolysis.
The resulting data and regression statistics for the quantitations appear in Table 5 , and the Lineweaver-Burk plot constructed from these data is shown inJFig. 38). Using the reverse-estimatorU): R + t/b {Sg2+R2Sb2 -(t*lb*)SaSb} 1/2 The conformation of the phosphate group at either the 2-or 3-position is the same (equatorial) for both esters, but the probable difference in the configuration of the two esters relative to the enzyme and their proximity to carbon atoms bearing markedly different functional group (see Fig. 1 ) must be sufficient to acccount for the difference in the hydrolysis of these compounds.
In vivo Studies
The bioactivity of the mono-phosphate esters of clindamycin as measured by in vitro methods was of a low order, i.e. <10mcg/mgand this small amount of activity could be accounted for as clindamycin base released by hydrolysis of the esters by the assay organism.
Data summarizing the relative abilities of clindamycin and the two phosphate esters to protect mice from a standardized S.aureus infection are summarized in Table 6 . Both (calcium salt) intramuscularly is shown in Fig. 4 . The serum is typical in that only clindamycin is present. However, in the urine two slow moving zones are observed.
The slowest, Rf 0.14, is consistent with the l'-demethyl analog of clindamycin while the zone at Rf 0.32 is most probably the sulfoxide of clindamycin. The latter has been observed in a number of studies involving dogs and rats using clindamycin. A TLC bioautogram of rat urine from animals given the 3-ester (15mg/animal) is shown inJFig. 5. This is typical of clindamycin metabolism in rats in which the slower moving r-demethyl analog is the principal metabolite and little if any sulfoxide is observed. LL-lower 95 % confidence limit. UL=upper 95 % confidence limit. SE=standard error of the mean s/Vn.
